CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Income Taxes Paid
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Income Taxes Paid of $17.78 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income taxes paid, net for the quarter ending 2026-06-27 was $16.05M, a 71.68% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income taxes paid, net for the quarter ending 2026-03-28 was $1.73M, a 90.03% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income taxes paid, net for the quarter ending 2025-12-27 was $26.95M, a 14.41% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income taxes paid, net for the quarter ending 2025-09-27 was $18.70M, a 18.28% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income taxes paid, net for fiscal 2025 was $119.64M, a 5.12% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income taxes paid, net for fiscal 2024 was $126.10M, a 39.49% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income taxes paid, net for fiscal 2023 was $90.40M, a 19.09% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. income taxes paid, net for fiscal 2022 was $75.91M, a 0.62% increase from fiscal 2021.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month | Income Taxes Paid, Net 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-27 | $16.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $17.78M 10-Q · filed 2026-08-05 | $44.73M derived: sum of 3 quarters · filed 2026-08-05 | $63.43M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-28 | $1.73M 10-Q · filed 2026-05-07 | $28.68M derived: sum of 2 quarters · filed 2026-05-07 | $47.38M derived: sum of 3 quarters · filed 2026-05-07 | $104.05M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-27 | $26.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $45.66M derived: sum of 2 quarters · filed 2026-02-18 | $102.32M derived: sum of 3 quarters · filed 2026-08-05 | $119.64M 10-K · filed 2026-02-18 | |
| 2025-09-27 | $18.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $75.37M derived: sum of 2 quarters · filed 2026-08-05 | $92.69M 10-Q · filed 2025-11-05 | $124.18M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-28 | $56.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $73.99M 10-Q · filed 2026-08-05 | $105.48M derived: sum of 3 quarters · filed 2026-08-05 | $128.37M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-29 | $17.32M 10-Q · filed 2026-05-07 | $48.81M derived: sum of 2 quarters · filed 2026-05-07 | $71.70M derived: sum of 3 quarters · filed 2026-05-07 | $124.70M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-28 | $31.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $54.38M derived: sum of 2 quarters · filed 2026-02-18 | $107.37M derived: sum of 3 quarters · filed 2026-02-18 | $126.10M 10-K · filed 2026-02-18 | $126.06M 10-K · filed 2025-02-19 |
| 2024-09-28 | $22.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $75.88M derived: sum of 2 quarters · filed 2025-11-05 | $94.61M 10-Q · filed 2025-11-05 | $109.23M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2024-06-29 | $52.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $71.72M 10-Q · filed 2025-08-06 | $86.34M derived: sum of 3 quarters · filed 2026-02-18 | $100.31M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2024-03-30 | $18.73M 10-Q · filed 2025-05-07 | $33.34M derived: sum of 2 quarters · filed 2026-02-18 | $47.31M derived: sum of 3 quarters · filed 2026-02-18 | $95.51M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2023-12-30 | $14.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $28.58M derived: sum of 2 quarters · filed 2026-02-18 | $76.78M derived: sum of 3 quarters · filed 2026-02-18 | $90.40M 10-K · filed 2026-02-18 | $90.37M 10-K · filed 2024-02-14 |
| 2023-09-30 | $13.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $62.16M derived: sum of 2 quarters · filed 2024-11-06 | $75.78M 10-Q · filed 2024-11-06 | ||
| 2023-07-01 | $48.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $61.82M 10-Q · filed 2024-08-07 | |||
| 2023-04-01 | $13.62M 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | $75.91M 10-K · filed 2025-02-19 | ||||
| 2021-12-25 | $75.44M 10-K · filed 2024-02-14 | ||||
| 2020-12-26 | $60.06M 10-K · filed 2023-02-22 | ||||
| 2019-12-28 | $54.06M 10-K · filed 2022-02-16 | ||||
| 2018-12-29 | $67.60M 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |